Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk

Project description

Personalised digital modelling for safer atrial fibrillation treatment

Atrial fibrillation has become one of the fastest-growing health challenges worldwide. It substantially elevates the risk of heart failure, hospitalisation and mortality. Unfortunately, ablative treatments are difficult to personalise, leading potentially to deteriorating cardiac performance. Supported by the Marie Skłodowska-Curie Actions programme, the AFHF-TAILOR project will create a personalised platform using advanced computer modelling, machine learning and clinical evidence for the optimisation of treatment tailored to specific patients’ needs. Through simulations of cardiac performance in thousands of virtual patients, along with clinical validation of the findings, the proposed approach will help identify patients who stand to gain from the procedure without increasing their chances of developing heart failure.

Objective

Atrial fibrillation (AF) is projected to affect one in three adults by 2060 . Patients with AF are at increased risk of heart failure (HF) and death. Indeed, more than half (57%) of subjects with new-onset HF already have AF and are associated with higher hospitalisation and mortality rates. Remarkably, AF alone represents 2% of the global healthcare expenditure.

Catheter ablation is the most effective therapy for AF patients. However, 50% of patients experience recurrence after the first ablation, requiring additional and more extensive ablations. Paradoxically, while an extensive ablation lesion might be more effective for preventing AF, it could also result in atrial mechanical dysfunction, increasing the risk for HF. Thus, the ability to accurately identify patients in which ablation could lead to HF, and stratify them to optimal treatments to reduce the risk of both diseases would be of tremendous clinical value.

In this fellowship, I propose to address the unmet need of personalising AF therapy to minimise the risk of HF (AFHF-TAILOR) by integrating whole-organ computer simulations powered by artificial intelligence (AI) and clinical data. The project takes in-silico studies to the next level, by integrating electro-mechanical simulations in thousands of virtual patients. Moreover, to ensure that the computer framework meets the needs for clinical translation, a dedicated AI framework will be trained on the simulations to enable rapid and accurate estimations of personalised cardiac mechanics. Two distinct clinical datasets, with important information such as cardiac imaging, catheter ablation lesions and mechanical biomarkers, will be used to externally validate the AI algorithm and the computer simulations. Accordingly, the project will provide a robust digital framework that balances ablation efficacy with the preservation of atrial function, ultimately reducing the risk of both diseases, AF and HF.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Net EU contribution
€ 292 118,88
Address
Raemistrasse 101
8092 Zuerich
Switzerland
Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)